Gene therapy for haemophilia B.
AAV virus mediated transfer of factor IX to humans is safe and effective at three dose levels. Two subjects treated at highest dose level developed immune mediated transaminitis which resolved on a short course of Prednisolone. Beneficial effects in terms of continuous elevation of factor IX level above base line was seen in all subjects, continuing for over 18 months. Further study of this treatment method is warranted.
The Katharine Dormandy Haemophilia Centre and Thrombosis Unit, Royal Free National Health Service Trust, London, UK. e.tuddenham@ucl.ac.uk
E
E
Tuddenham
D000256:Adenoviridae / Q000235:genetics; D000229:Dependovirus; D005164:Factor IX / Q000008:administration & dosage / Q000235:genetics; D018014:Gene Transfer Techniques; D015316:Genetic Therapy / Q000379:methods*; D005822:Genetic Vectors; D002836:Hemophilia B / Q000235:genetics / Q000628:therapy*; D006801:Humans
D005164:Factor IX